| 40.75 0.46 (1.14%) | 05-08 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 52.31  |
1-year : | 56.68 |
| Resists | First : | 44.79 |
Second : | 48.52 |
| Pivot price | 42.9  |
|||
| Supports | First : | 38.74 |
Second : | 32.23 |
| MAs | MA(5) : | 41.08 |
MA(20) : | 43.47 |
| MA(100) : | 30.5 |
MA(250) : | 24.33 |
|
| MACD | MACD : | 0.6 |
Signal : | 1.5 |
| %K %D | K(14,3) : | 11.9 |
D(3) : | 13.9 |
| RSI | RSI(14): 48.2 |
|||
| 52-week | High : | 48.52 | Low : | 14.78 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ ELVN ] has closed above bottom band by 21.3%. Bollinger Bands are 16% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 43 - 43.29 | 43.29 - 43.55 |
| Low: | 39.34 - 39.69 | 39.69 - 40.01 |
| Close: | 40.21 - 40.76 | 40.76 - 41.26 |
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors include ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial has been activated to evaluate people with cancers harboring an abnormal HER2 gene. The company is based in Boulder, Colorado.
Fri, 08 May 2026
Enliven: Drug candidate ‘has the potential to be the best-in-class’ - BizWest
Thu, 07 May 2026
Q1 2026: Enliven Therapeutics (NASDAQ: ELVN) narrows loss, holds $452M cash - Stock Titan
Thu, 07 May 2026
Enliven Therapeutics (NASDAQ: ELVN) narrows loss and targets Phase 3 trial - Stock Titan
Thu, 07 May 2026
Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update - ChartMill
Thu, 07 May 2026
Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update - PR Newswire
Wed, 06 May 2026
Terns Buyout Deal Ignites Optimism For Enliven Therapeutics’s Blood Cancer Portfolio - MSN
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 61 (M) |
| Shares Float | 34 (M) |
| Held by Insiders | 7.5 (%) |
| Held by Institutions | 105 (%) |
| Shares Short | 5,370 (K) |
| Shares Short P.Month | 8,220 (K) |
| EPS | -1.84 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 7.73 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -18.7 % |
| Return on Equity (ttm) | -27 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.97 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -70 (M) |
| Levered Free Cash Flow | -48 (M) |
| PE Ratio | -22.27 |
| PEG Ratio | 0 |
| Price to Book value | 5.27 |
| Price to Sales | 0 |
| Price to Cash Flow | -35.31 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|